Science & Pipeline
Roca Therapeutics aims to be a holistic disease-driven company addressing ocular diseases.
Redefining severe retinal disease care with a disease-modifying first-in-class topical therapy
to treat uveal melanoma from an ophthalmology and oncology lens.
Our Science
Roca Therapeutics’ novel approach for ocular diseases is based on over a decade of foundational scientific research across medicinal chemistry, oncology, ophthalmology and immunology from the co-founders Dr. Gilles Pagès, Dr. Maeva Dufies, Dr. Cyril Ronco and Dr. Rachid Benhida.
We are advancing our lead translational research programs, RCT001 and RCT002 as building blocks towards a promising portfolio of patent protected first-In-class small molecules.
Our objective is to address exacerbated/resistant mechanisms of angiogenesis, chronic inflammation and oxidative stress in the context of neoplastic and neovascular disorders.
Our Pipeline
Roca Therapeutics is a holistic disease-driven company addressing uveal melanoma (rare aggressive ocular cancer) from an ophthalmology and oncology treatment perspective with RCT001 and also address radiation-induced maculopathy with RCT002 as a direct result of proton therapy, which seriously and permanently affects visual acuity.
Designed for severe highly aggressive ocular diseases
Our lead candidate, RCT002, is less than 12 months from IND/CTA submission and has shown promising efficacy and pharmacological data. Developed for topical administration, RCT002 offers a unique product profile. With a non-invasive route of administration, RCT002 modifies disease by blocking resistant angiogenesis, oxidative stress, inflammation, and fibrosis.
RCT002 is backed by solid translational and mechanistic data. We have designed a robust disease, clinical, and regulatory strategy targeting radiation-induced maculopathy (an orphan disease) and diabetic macular edema as a target second indication.
Ecosystem & Partners
